UPSTREAM BIO, INC. Lease, Cost
UPSTREAM BIO, INC. (UPB) reported Lease, Cost of $739.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-26.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:LeaseCost · last filed 2026-03-26
- UPSTREAM BIO, INC. lease, cost for fiscal 2025 was $739.00K, a 54.93% increase from fiscal 2024.
- UPSTREAM BIO, INC. lease, cost for fiscal 2024 was $477.00K, a 59.53% increase from fiscal 2023.
- UPSTREAM BIO, INC. lease, cost for fiscal 2023 was $299.00K.
| Period end | Lease, Cost 12 month |
|---|---|
| 2025-12-31 | $739.00K 10-K · filed 2026-03-26 |
| 2024-12-31 | $477.00K 10-K · filed 2026-03-26 |
| 2023-12-31 | $299.00K 10-K · filed 2025-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |